BACKGROUND: Rotavirus vaccines are less effective in developing countries versus developed countries. One hypothesis for this difference in performance is that higher levels of maternal antibodies in developing countries may interfere with vaccine response, suggesting that delayed dosing could be beneficial. The present analysis aims to assess whether rotavirus vaccine effectiveness (VE) varies by age at vaccination during routine use in Bolivia. METHODS: Data were merged from 2 postlicensure evaluations of monovalent rotavirus vaccine (RV1) in Bolivia, where 2 doses of RV1 are recommended at 2 and 4 months of age. For each dose, children were classified as receiving each dose "early," "on-time" or "late." Stratified unconditional logistic regression models were used to estimate VE, using unvaccinated children as the referent. VE was calculated as (1 - odds ratio) × 100%. Models were adjusted for hospital, age and time since RV1 introduction (via including terms for month and year of birth). RESULTS: VE for 2 doses of RV1 tended to be higher in infants receiving the first dose early (VE, 92%; 95% confidence interval: 70%-98%), when compared with infants receiving their first dose on-time [72% (62%-81%)] or late [68% (51%-79%)]. Estimates of VE were not substantially different when comparing children by age at second dose [early: VE, 76% (50%-89%); on-time: VE, 70% (50%-89%); late: VE, 75% (60%, 84%)], including all children. CONCLUSIONS: Our results indicate that early administration may improve VE and support the current World Health Organization recommendations for the RV1 schedule.
BACKGROUND: Rotavirus vaccines are less effective in developing countries versus developed countries. One hypothesis for this difference in performance is that higher levels of maternal antibodies in developing countries may interfere with vaccine response, suggesting that delayed dosing could be beneficial. The present analysis aims to assess whether rotavirus vaccine effectiveness (VE) varies by age at vaccination during routine use in Bolivia. METHODS: Data were merged from 2 postlicensure evaluations of monovalent rotavirus vaccine (RV1) in Bolivia, where 2 doses of RV1 are recommended at 2 and 4 months of age. For each dose, children were classified as receiving each dose "early," "on-time" or "late." Stratified unconditional logistic regression models were used to estimate VE, using unvaccinated children as the referent. VE was calculated as (1 - odds ratio) × 100%. Models were adjusted for hospital, age and time since RV1 introduction (via including terms for month and year of birth). RESULTS: VE for 2 doses of RV1 tended to be higher in infants receiving the first dose early (VE, 92%; 95% confidence interval: 70%-98%), when compared with infants receiving their first dose on-time [72% (62%-81%)] or late [68% (51%-79%)]. Estimates of VE were not substantially different when comparing children by age at second dose [early: VE, 76% (50%-89%); on-time: VE, 70% (50%-89%); late: VE, 75% (60%, 84%)], including all children. CONCLUSIONS: Our results indicate that early administration may improve VE and support the current World Health Organization recommendations for the RV1 schedule.
Authors: A D Steele; J Reynders; F Scholtz; P Bos; M C de Beer; J Tumbo; C F Van der Merwe; A Delem; B De Vos Journal: J Infect Dis Date: 2010-09-01 Impact factor: 5.226
Authors: Joann F Gruber; Darcy A Hille; G Frank Liu; Susan S Kaplan; Micki Nelson; Michelle G Goveia; T Christopher Mast Journal: Pediatr Infect Dis J Date: 2017-01 Impact factor: 2.129
Authors: A D Steele; B De Vos; J Tumbo; J Reynders; F Scholtz; P Bos; M C de Beer; C F Van der Merwe; A Delem Journal: Vaccine Date: 2008-09-09 Impact factor: 3.641
Authors: Daniel C Payne; Rangaraj Selvarangan; Parvin H Azimi; Julie A Boom; Janet A Englund; Mary Allen Staat; Natasha B Halasa; Geoffrey A Weinberg; Peter G Szilagyi; James Chappell; Monica McNeal; Eileen J Klein; Leila C Sahni; Samantha H Johnston; Christopher J Harrison; Carol J Baker; David I Bernstein; Mary E Moffatt; Jacqueline E Tate; Slavica Mijatovic-Rustempasic; Mathew D Esona; Mary E Wikswo; Aaron T Curns; Iddrisu Sulemana; Michael D Bowen; Jon R Gentsch; Umesh D Parashar Journal: Clin Infect Dis Date: 2015-10-08 Impact factor: 9.079
Authors: Manish M Patel; Maritza Patzi; Desiree Pastor; Aleida Nina; Yelin Roca; Leovigildo Alvarez; Volga Iniguez; Rosario Rivera; Ka Ian Tam; Osbourne Quaye; Michael Bowen; Umesh Parashar; Lucia Helena De Oliveira Journal: BMJ Date: 2013-06-19
Authors: Adam W J Jenney; Rita Reyburn; Felisita T Ratu; Evelyn Tuivaga; Cattram Nguyen; Sokoveti Covea; Sarah Thomas; Eric Rafai; Rachel Devi; Kathryn Bright; Kylie Jenkins; Beth Temple; Lisi Tikoduadua; Joe Kado; E Kim Mulholland; Carl D Kirkwood; Kimberley K Fox; Julie E Bines; Varja Grabovac; Aalisha Sahu Khan; Mike Kama; Fiona M Russell Journal: Lancet Reg Health West Pac Date: 2020-11-25